We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M Turnover 20%
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+39.14%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$305M
AUM Growth
-$3.01M
Cap. Flow
-$113M
Cap. Flow %
-36.99%
Top 10 Hldgs %
100%
Holding
14
New
–
Increased
–
Reduced
2
Closed
6
Avg Time Held
1.9 years
Top 10 Avg Time Held
1.9 years
Top 20 Avg Time Held
1.9 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RDUS icon
Radius Health, Inc.
RDUS
+$98.8M
2
PETX
Aratana Therapeutics, Inc.
PETX
+$7.21M
3
NVRO icon
NEVRO CORP.
NVRO
+$5.34M
4
SVRA icon
Savara
SVRA
+$1.2M
5
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$178K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RDUS icon
1
DELISTED
Radius Health, Inc.
RDUS
$210M 68.88%
3,887,502
-1,943,751
-33% -$98.8M
2014 Q2
9 quarters
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.21B
$32.9M 10.77%
2,168,691
– –
2016 Q1
2 quarters
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$17M 5.58%
1,729,674
– –
2013 Q2
13 quarters
CHMA
4
DELISTED
Chiasma, Inc. Common Stock
CHMA
$16.9M 5.52%
5,736,296
– –
2015 Q3
4 quarters
ELGX
5
DELISTED
Endologix Inc
ELGX
$14.4M 4.7%
112,145
– –
2016 Q1
2 quarters
TARA icon
6
Protara Therapeutics
TARA
$147M
$9.18M 3.01%
24,585
– –
2014 Q4
7 quarters
HSTO
7
DELISTED
Histogen Inc. Common Stock
HSTO
$2.38M 0.78%
5,960
– –
2013 Q3
12 quarters
PETX
8
DELISTED
Aratana Therapeutics, Inc.
PETX
$2.34M 0.77%
250,000
-867,875
-78% -$7.21M
2013 Q2
13 quarters
MGNX icon
9
MacroGenics
MGNX
$211M
– –
-3,168
Closed -$86K –
SGMO icon
10
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-22,487
Closed -$130K –
SVRA icon
11
Savara
SVRA
$978M
– –
-36,455
Closed -$1.2M –
NVRO icon
12
DELISTED
NEVRO CORP.
NVRO
– –
-72,413
Closed -$5.34M –
CLCD
13
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-21,806
Closed -$178K –
ETRM
14
DELISTED
EnteroMedics Inc.
ETRM
– –
-1,060
Closed -$22K –

Similar funds

WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

MPM Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, MPM Asset Management held 14 positions worth $305M, down 0.98% from $308M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM Asset Management withdrew a net $113M in Q3 2016, closing 6 positions and reducing 2 holdings. Its most notable exit was NEVRO CORP., an estimated $5.34M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM Asset Management's biggest Q3 2016 reduction was Radius Health, Inc., cutting an estimated $98.8M.
  • MPM Asset Management fully exited NEVRO CORP. in Q3 2016, selling an estimated $5.34M.
  • MPM Asset Management's ten largest holdings make up 100% of its $305M portfolio in Q3 2016.
  • MPM Asset Management opened 0 new positions and closed 6 in Q3 2016.
  • MPM Asset Management's portfolio value fell 0.98% quarter-over-quarter to $305M.

Based on MPM Asset Management's 13F filing for Q3 2016, filed 10 Nov 2016.